Haemophilus influenzae: Structure, Genetics, and Resistance Mechanisms

Haemophilus influenzae is a small, Gram-negative bacterium that colonizes the human respiratory tract and, under the right conditions, causes infections ranging from ear infections and sinusitis to pneumonia and meningitis. Despite its name, it does not cause influenza; that confusion dates to 1892, when the organism was mistakenly thought to be the culprit behind flu pandemics. What makes H. influenzae a persistent clinical challenge is the interplay between its adaptable surface structures, a genome shaped by natural competence for taking up foreign DNA, and a growing arsenal of antibiotic resistance mechanisms that complicate treatment.

The Cell Envelope

Like other Gram-negative bacteria, H. influenzae has a double-membrane cell envelope: an inner cytoplasmic membrane, a thin layer of peptidoglycan in the periplasmic space, and an outer membrane studded with proteins and lipooligosaccharide (LOS). The outer membrane is not just a passive barrier. Its major proteins anchor the bacterium’s interactions with the host, and their integrity determines how well the cell resists environmental stress. One well-studied outer membrane protein, P5, has a domain at its inner end that physically binds the peptidoglycan layer, tethering the outer membrane to the cell wall. When researchers removed this protein or its peptidoglycan-binding domain, the entire outer membrane protein profile changed, suggesting that P5 helps stabilize the membrane and, by extension, the bacterium’s ability to interact with host tissues.¹

The LOS on the outer surface is shorter and more variable than the lipopolysaccharide found in organisms like E. coli, and it plays a central role in immune evasion. H. influenzae modifies its LOS structures to avoid complement attack, a strategy shared with other respiratory pathogens.² The LOS composition itself can shift through phase variation, a genetic trick discussed further below.

Capsule Types and Nontypeable Strains

Some H. influenzae strains are wrapped in a polysaccharide capsule that sits outside the outer membrane, and these are classified into six serotypes (a through f) based on the capsule’s chemical composition. Serotype b (Hib) has historically been the most dangerous. Its capsule is a polymer of ribose and ribitol phosphate, called polyribosyl ribitol phosphate (PRP), and it is a critical virulence factor because it helps the bacterium evade phagocytosis and complement-mediated killing.³ The PRP capsule is also the target for the Hib conjugate vaccine, which trains the immune system to produce antibodies against this specific sugar polymer.⁴ Research has shown that the PRP is anchored to the cell surface through a covalently attached phospholipid, which likely helps keep it from simply floating away.⁵

Most H. influenzae strains found in the respiratory tract, however, lack a polysaccharide capsule entirely. These nontypeable H. influenzae (NTHi) strains are genetically diverse, with genomic studies identifying seven major subclades and well over a hundred distinct sequence types.⁶ Whole-genome sequencing of NTHi has shown a predominantly clonal population structure, meaning genetic information is mostly passed from parent to daughter cell rather than being shuffled horizontally, though horizontal transfer does still occur.⁷ A small fraction of NTHi isolates, roughly one in ten in one study, carry an insertion element called IS1016 that is normally associated with encapsulated strains, hinting that some capsule-less strains may have descended from encapsulated ancestors that lost their capsule genes.⁸

Genetics of the Capsule Locus

The genes responsible for building and exporting the capsule are clustered in a single chromosomal region called the cap locus. In serotype b strains, an unusual feature stands out: more than 98% of natural isolates carry a duplication of roughly 17 kilobases of DNA within this locus.⁹ Having two copies of these capsule genes doubles the amount of PRP the bacterium produces, a gene-dosage effect that has been measured directly by comparing duplication-carrying strains to rare single-copy strains. The single-copy strains make about half as much capsule polysaccharide.

This duplication is a double-edged sword, however. Because the two copies are arranged as direct repeats, the bacterium’s own recombination machinery can delete one copy, creating a daughter cell that has lost essential export genes and can no longer produce a capsule. One key export gene, bexA, sits at the boundary of the duplication, and a deletion at one end of the repeated region has removed most of one bexA copy. That means the bacterium’s ability to make a capsule depends on keeping the duplicated structure intact.¹⁰ Capsule loss through this recombination event generates non-encapsulated variants that are less virulent but may be better at mucosal colonization, giving the population as a whole flexibility to adapt to different niches.

Natural Competence and DNA Uptake

H. influenzae was actually the first organism in which natural genetic transformation was demonstrated, and it remains one of the best-studied naturally competent bacteria. When conditions are right, the cell takes up naked DNA from the environment, incorporates it into its chromosome by recombination, and can thereby acquire new genes, including resistance genes. But this process is not random. The uptake machinery is strongly biased toward DNA that contains a specific short sequence, called an uptake sequence (USS), with a nine-base-pair core. Only four bases within that core are truly critical for uptake to proceed.¹¹

This uptake sequence is massively overrepresented in the H. influenzae genome itself, appearing roughly every kilobase. The practical effect is that the bacterium preferentially takes up DNA from its own species or close relatives, where the USS is abundant, and largely ignores DNA from distantly related organisms. Experiments measuring uptake across the entire genome found that short DNA fragments carrying a USS are taken up about a thousand-fold more efficiently than fragments without one.¹² Once inside the cell, the DNA needs to be processed for recombination into the chromosome. A gene called dprA encodes a protein essential for this chromosomal integration step, though it is not required when plasmid DNA is taken up.¹³

Phase Variation

H. influenzae has another genetic strategy for rapid adaptation: phase variation, the reversible on-off switching of gene expression. The engine behind most phase variation in this species is simple sequence repeats (SSRs), short stretches of DNA where a motif of a few nucleotides is repeated in tandem. When the cell copies its DNA, these tandem repeats are prone to slipping, adding or losing repeat units. If the repeat tract sits inside or upstream of a gene, a change in the number of repeats shifts the reading frame or alters how much of the gene’s product gets made. Four-nucleotide (tetranucleotide) repeats are the dominant mediators of phase variation in H. influenzae, and comparative genomic analysis has identified numerous loci across the species’ pan-genome where these repeats can drive switching.¹⁴

A well-characterized example involves the HMW1A adhesin, a surface protein important for binding to host cells. Expression of HMW1A is inversely proportional to the length of a seven-nucleotide SSR upstream of its gene: as the repeat tract grows longer, less adhesin is made, and vice versa. Recent work has shown that this SSR-driven regulation also requires a specific RNA element in the untranslated region of the gene’s messenger RNA, targeted by the enzyme RNase III.¹⁵ Phase variation lets a clonal population hedge its bets: at any given time, some cells display a particular surface structure and others do not, ensuring that part of the population is pre-adapted when conditions change.

Beta-Lactam Resistance

Beta-lactam antibiotics, including ampicillin and amoxicillin, were once the workhorses against H. influenzae infections. Two distinct resistance mechanisms have eroded their effectiveness. The first is production of beta-lactamase enzymes that break down the antibiotic before it can act. Beta-lactamase production is now widespread globally and is the main cause of ampicillin resistance.¹⁶ In many settings, adding a beta-lactamase inhibitor such as clavulanate to amoxicillin can overcome this mechanism.

The second mechanism is more insidious and harder to counter. Some strains carry mutations in the gene encoding penicillin-binding protein 3 (PBP3), which is the target that beta-lactams bind to in order to kill the cell. Altered PBP3 has a lower affinity for the drug, so the antibiotic cannot do its job even without an enzyme to destroy it. These strains are known by the acronyms BLNAR (beta-lactamase-negative ampicillin-resistant) and BLPACR (beta-lactamase-positive amoxicillin-clavulanate-resistant), depending on whether they also produce a beta-lactamase on top of the PBP3 changes. Several specific amino acid substitutions in PBP3 have been pinpointed as the main drivers of resistance. The substitution of lysine for asparagine at position 526 (N526K) alone increased resistance to imipenem eightfold and to various cephalosporins two- to eightfold in lab experiments. Adding further substitutions at positions 385 and 389 boosted cephalosporin resistance by an additional two- to fourfold.¹⁷ These PBP3-altered strains have been rising in prevalence, especially in Japan, and threaten the usefulness of expanded-spectrum cephalosporins for serious infections such as meningitis.¹⁸

Fluoroquinolone Resistance

Fluoroquinolones like ciprofloxacin target two essential enzymes in the bacterium: DNA gyrase and topoisomerase IV, both of which manage the coiling and uncoiling of DNA during replication. Resistance arises through mutations in the genes encoding these enzymes, specifically in the subunits GyrA and ParC. Amino acid changes at positions Ser-84 and Asp-88 in GyrA, and at the analogous positions in ParC, are the key resistance mutations. Strains generally need at least one substitution in each of these two enzymes to reach clinically meaningful levels of resistance, and the degree of resistance scales with the number of mutations accumulated.¹⁹²⁰

An important wrinkle is that fluoroquinolone resistance in H. influenzae appears linked to hypermutability. In lab experiments, only strains with elevated mutation rates were able to generate ciprofloxacin-resistant variants. These hypermutable strains accumulated resistance in a stepwise fashion: first target modifications, then loss of an outer membrane porin, and finally increased drug efflux.²¹ This connection between hypermutation and resistance is concerning because it means that once a strain is on the hypermutable track, it can pile up resistance to multiple drug classes simultaneously.

Macrolide Resistance and the Efflux System

Macrolides such as azithromycin are frequently used for respiratory infections, and resistance in H. influenzae has emerged through two broad categories. The more common route involves changes in the ribosomal target or in regulatory proteins, including substitutions in ribosomal proteins L4 and L22, mutations in the acrR gene that controls efflux, and changes in the 23S ribosomal RNA. These mechanisms were found in about 85% of macrolide-resistant H. influenzae strains in one large study. A smaller fraction of resistant strains carry acquired resistance genes, particularly mef(E) and msr(D), which encode an efflux pump and a ribosomal protection protein, respectively.²²

Beyond macrolide-specific pumps, H. influenzae possesses a general-purpose efflux system called AcrAB-TolC. This tripartite pump spans the entire cell envelope and can expel a variety of structurally unrelated compounds, contributing to baseline resistance levels against multiple drug classes. Knocking out any component of the pump, whether the inner membrane transporter AcrB or the outer membrane channel TolC, increases the bacterium’s susceptibility to drugs it would otherwise tolerate.²³ The TolC component was identified as a homolog of the well-characterized E. coli TolC by showing that its inactivation phenocopied AcrB knockout in susceptibility assays.²⁴

Biofilm Formation and Chronic Infection

NTHi strains commonly form biofilms, structured communities of bacteria encased in a self-produced matrix. This is directly relevant to chronic and recurrent infections like otitis media and exacerbations of chronic obstructive pulmonary disease (COPD). The biofilm matrix in NTHi has been shown to contain proteins, extracellular DNA (eDNA), extracellular RNA, and a beta-glucan polysaccharide. The eDNA is an essential scaffold: removing it destabilizes established biofilms. Extracellular RNA, by contrast, appears important mainly during the early stages of biofilm assembly.²⁵

Biofilm formation is not a fixed trait; it is subject to epigenetic regulation through the phasevarion system. NTHi strains that express the ModA2 methyltransferase, a phase-variable DNA methylase, form biofilms with significantly greater biomass under alkaline conditions compared to strains lacking ModA2. Paradoxically, these denser biofilms contained less eDNA and less of the DNABII protein HU, which normally provides structural stability. The implication is that the phasevarion reprograms the biofilm’s architecture and composition, potentially affecting how well antibiotics and immune cells penetrate.²⁶

Immune Evasion Strategies

Beyond the capsule, H. influenzae uses several molecular tools to dodge the host immune response. One of the best-known is the IgA protease, an enzyme that cuts human IgA1, the dominant antibody on mucosal surfaces, right at the hinge region that connects the antigen-binding arms to the rest of the molecule. This neutralizes the antibody’s ability to aggregate and clear bacteria. The IgA protease also promotes bacterial invasion of respiratory epithelial cells and trafficking inside them, helping the organism persist in the airway.²⁷

H. influenzae also hijacks the host’s own complement-regulation machinery. It decorates its surface with host proteins, factor H and C4b-binding protein, that normally exist to keep complement from accidentally attacking the body’s own cells. By recruiting these regulators, the bacterium dampens both the classical and alternative complement pathways, reducing the opsonization and lysis that would otherwise destroy it.² On top of this, the organism is capable of invading host cells through multiple pathways and can pass between epithelial cells to reach the subepithelial space, giving it access to deeper tissues where surface-level immune defenses are less effective.

Iron Acquisition and Growth Requirements

H. influenzae has a well-known laboratory quirk: it cannot grow without two external supplements, hemin (X factor, a source of iron-containing porphyrin) and NAD (V factor, a coenzyme).²⁸ This dependence on exogenous hemin reflects the fact that the bacterium cannot synthesize the porphyrin ring on its own, so it must scavenge it from the host environment. In the human body, free iron is kept vanishingly scarce by carrier proteins like transferrin and lactoferrin, a defense strategy sometimes called nutritional immunity. H. influenzae counters this by expressing a receptor that strips iron directly from human transferrin. All H. influenzae isolates tested in one study showed transferrin-binding activity, while lactoferrin binding was rare, detected in only one of fifteen isolates.²⁹ The transferrin receptor is highly specific for the human protein, which may help explain why H. influenzae is an exclusively human pathogen.³⁰

Vaccine Impact and Strain Replacement

The introduction of the Hib conjugate vaccine in the late 1980s and early 1990s dramatically reduced invasive disease caused by serotype b. In countries with high vaccination coverage, Hib meningitis and sepsis in children have become rare. But vaccination against one serotype created an ecological opening. Surveillance in Italy over ten years of routine Hib vaccination documented a drastic decline in overall invasive H. influenzae cases, but a clear shift: the dominant strains causing disease changed from Hib to unencapsulated (nontypeable) organisms, and disease in the elderly increased slightly.³¹

Canadian data showed a similar pattern. Infant Hib vaccination reduced Hib disease across all age groups, including unvaccinated adults, consistent with a herd effect. However, in children under five, invasive disease due to nontypeable and serotype f strains roughly doubled and tripled, respectively. Invasive H. influenzae disease now commonly presents as bloodstream infection in older adults caused by nontypeable strains.³² This strain replacement underlines why NTHi biology, resistance mechanisms, and biofilm behavior matter so much for current clinical practice: the organisms causing most H. influenzae disease today are the capsule-less strains that the existing vaccine does not target.

Interactions with Other Respiratory Bacteria

In the upper airway, H. influenzae shares space with other common colonizers, notably Streptococcus pneumoniae and Moraxella catarrhalis. The relationships among these species are not static and depend on context. In healthy children, the three organisms coexisted without strong competitive effects on one another. But at the onset of acute otitis media, the dynamics shifted markedly. H. influenzae colonization was negatively associated with both S. pneumoniae and M. catarrhalis during infection: the presence of one pathogen lowered the odds of finding the others.³³ These competitive interactions during active infection may influence which pathogen dominates in a given episode and, by extension, which antibiotic resistance profile a clinician is likely to encounter.

Rapid Identification and Capsule Typing

Identifying H. influenzae in a clinical sample is straightforward enough with standard culture methods, particularly using chocolate agar supplemented with X and V factors. But determining whether a strain carries a capsule, and which serotype it belongs to, has traditionally required PCR-based capsule gene typing, a process that takes hours and specialized reagents. Several groups have evaluated MALDI-TOF mass spectrometry, which is already standard in many hospital labs for rapid bacterial identification, as an alternative approach to capsule typing. Because encapsulated H. influenzae serotypes belong to distinct genetic lineages, their protein profiles are sufficiently different from nontypeable strains to allow separation.³⁴³⁵ If this approach is validated more broadly, it could enable same-day serotype identification in routine microbiology workflows, which matters for epidemiological surveillance and for guiding decisions about whether an infection is vaccine-preventable.